Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chunrui Xie"'
Autor:
Lulu Hu, Ji Shi, Dachuan Shen, Xingyue Zhai, Dapeng Liang, Jing Wang, Chunrui Xie, Zhiyu Xia, Jing Cui, Feng Liu, Sha Du, Songshu Meng, Haozhe Piao
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-11 (2023)
Abstract The efficacy of osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has been evaluated in glioblastoma (GBM) through preclinical and clinical trials. However, the underlying mechanism of osimertinib-in
Externí odkaz:
https://doaj.org/article/4ce0d8735f434c6aa31bae8d23209919
Autor:
Kun Fang, Sha Du, Dachuan Shen, Zhipeng Xiong, Ke Jiang, Dapeng Liang, Jianxin Wang, Huizhe Xu, Lulu Hu, Xingyue Zhai, Yuting Jiang, Zhiyu Xia, Chunrui Xie, Di Jin, Wei Cheng, Songshu Meng, Yifei Wang
Publikováno v:
iScience, Vol 25, Iss 7, Pp 104618- (2022)
Summary: Ferroptosis is a new kind of regulated cell death that is characterized by highly iron-dependent lipid peroxidation. Cancer cells differ in their sensitivity to ferroptosis. Here we showed that the Suppressor of fused homolog (SUFU), a criti
Externí odkaz:
https://doaj.org/article/3e22ae84788c498681f7e4a2b41898cb
Autor:
songshu meng, lulu hu, ji shi, Dachuan Shen, Xingyue Zhai, Dapeng Liang, Jing Wang, Chunrui Xie, Zhiyu Xia, Jing Cui, Feng Liu, Sha Du, Haozhe Piao
Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has been evaluated in glioblastoma (GBM) in pre-clinical and clinical trials. However, the precise mechanism whereby Osimertinib induces GBM cell death
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e105b77bcf77a353be88de8c23fca28
https://doi.org/10.21203/rs.3.rs-1771552/v1
https://doi.org/10.21203/rs.3.rs-1771552/v1
Autor:
Jing Cui, Huizhe Xu, Ji Shi, Kun Fang, Dapeng Liang, Feng Liu, Jing Wang, Chunrui Xie, Zhiyu Xia, Songshu Meng, Yumei Yan, Haozhe Piao
Purpose: Immunogenic cell death (ICD), which releases danger-associated molecular patterns (DAMP) that induce potent anticancer immune response, has emerged as a key component of therapy-induced anti-tumor immunity. The aim of this work was to analyz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82ce711433c2a464bcb8856180536b4
https://doi.org/10.21203/rs.3.rs-1759379/v1
https://doi.org/10.21203/rs.3.rs-1759379/v1